

IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Please amend claims 31 and 80 as follows:

Please cancel claims 1-29 and 36-79 without prejudice.

Please add new claims 88-90.

STATUS OF CLAIMS

Claims 1-30 **(canceled)**

31. **(currently amended)** An isolated polypeptide comprising a the sequence of SEQ ID NO:2.

Claims 32-34 **(canceled)**

35. **(previously presented)** A composition comprising a polypeptide of claim 80 and an acceptable carrier or diluent.

Claims 36-79 **(canceled)**

Claim 80 **(currently amended)** An isolated polypeptide comprising an amino acid sequence at least 95% homologous to SEQ ID NO:2, wherein said polypeptide, when bound to a binding partner, stimulates an activity of the polypeptide.

Claim 81 **(previously presented)** The isolated polypeptide of claim 80, wherein said polypeptide is a seven transmembrane receptor.

Claim 82 **(previously presented)** The isolated polypeptide of claim 81, wherein said seven transmembrane receptor is a G-protein coupled receptor.

Claims 83-87 (**canceled**)

Claim 88 (**new**) The isolated polypeptide of claim 82 comprising an amino acid at least 99% homologous to SEQ ID NO:2.

Claim 89 (**new**) The isolated polypeptide of claim 82 wherein said activity is production of a second messenger molecule, neuropeptide binding or neuropeptide signaling.

Claim 90 (**new**) The isolated polypeptide of claim 82 wherein said second messenger molecule is cAMP, inositol triphosphate or diacylglycerol.